BridgeBio Pharma Statistics
Total Valuation
BBIO has a market cap or net worth of $12.08 billion. The enterprise value is $13.29 billion.
Important Dates
The last earnings date was Wednesday, October 29, 2025, after market close.
| Earnings Date | Oct 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BBIO has 192.71 million shares outstanding. The number of shares has increased by 4.48% in one year.
| Current Share Class | 192.71M |
| Shares Outstanding | 192.71M |
| Shares Change (YoY) | +4.48% |
| Shares Change (QoQ) | +0.70% |
| Owned by Insiders (%) | 4.41% |
| Owned by Institutions (%) | 82.39% |
| Float | 153.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 33.74 |
| Forward PS | 17.71 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 37.56 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.88
| Current Ratio | 3.88 |
| Quick Ratio | 3.52 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.67 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -43.47% |
| Return on Invested Capital (ROIC) | -161.27% |
| Return on Capital Employed (ROCE) | -74.01% |
| Revenue Per Employee | $484,630 |
| Profits Per Employee | -$1.09M |
| Employee Count | 730 |
| Asset Turnover | 0.43 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BBIO has paid $1.71 million in taxes.
| Income Tax | 1.71M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +148.65% in the last 52 weeks. The beta is 1.27, so BBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.27 |
| 52-Week Price Change | +148.65% |
| 50-Day Moving Average | 54.67 |
| 200-Day Moving Average | 42.56 |
| Relative Strength Index (RSI) | 62.84 |
| Average Volume (20 Days) | 2,732,049 |
Short Selling Information
The latest short interest is 17.35 million, so 9.01% of the outstanding shares have been sold short.
| Short Interest | 17.35M |
| Short Previous Month | 17.49M |
| Short % of Shares Out | 9.01% |
| Short % of Float | 11.33% |
| Short Ratio (days to cover) | 7.96 |
Income Statement
In the last 12 months, BBIO had revenue of $353.78 million and -$797.12 million in losses. Loss per share was -$4.18.
| Revenue | 353.78M |
| Gross Profit | 338.84M |
| Operating Income | -578.47M |
| Pretax Income | -803.98M |
| Net Income | -797.12M |
| EBITDA | -573.10M |
| EBIT | -578.47M |
| Loss Per Share | -$4.18 |
Full Income StatementBalance Sheet
The company has $645.94 million in cash and $1.86 billion in debt, giving a net cash position of -$1.21 billion or -$6.30 per share.
| Cash & Cash Equivalents | 645.94M |
| Total Debt | 1.86B |
| Net Cash | -1.21B |
| Net Cash Per Share | -$6.30 |
| Equity (Book Value) | -1.92B |
| Book Value Per Share | -10.03 |
| Working Capital | 622.78M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$584.82 million and capital expenditures -$1.11 million, giving a free cash flow of -$585.93 million.
| Operating Cash Flow | -584.82M |
| Capital Expenditures | -1.11M |
| Free Cash Flow | -585.93M |
| FCF Per Share | -$3.04 |
Full Cash Flow StatementMargins
Gross margin is 95.78%, with operating and profit margins of -163.51% and -225.31%.
| Gross Margin | 95.78% |
| Operating Margin | -163.51% |
| Pretax Margin | -227.26% |
| Profit Margin | -225.31% |
| EBITDA Margin | -161.99% |
| EBIT Margin | -163.51% |
| FCF Margin | n/a |
Dividends & Yields
BBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.48% |
| Shareholder Yield | -4.48% |
| Earnings Yield | -6.60% |
| FCF Yield | -4.85% |
Dividend DetailsAnalyst Forecast
The average price target for BBIO is $73.89, which is 17.92% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $73.89 |
| Price Target Difference | 17.92% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (5Y) | 68.72% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BBIO has an Altman Z-Score of -4.49 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.49 |
| Piotroski F-Score | 3 |
